<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318847</url>
  </required_header>
  <id_info>
    <org_study_id>OND-URG</org_study_id>
    <nct_id>NCT04318847</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial</brief_title>
  <official_title>Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lizar Aguirre Pascasio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is intended to evaluate the efficacy and safety of the administration of
      ondansetron in children with mild-moderate dehydration.

      The target population will be children between 4 and 13 years old who present vomiting.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of children who return to medical/pediatric consultation for de same episode</measure>
    <time_frame>An average of 24 months</time_frame>
    <description>Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Vomiting in Infants and/or Children</condition>
  <arm_group>
    <arm_group_label>Ondransetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual Clinical Practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual Clinical Practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 MG</intervention_name>
    <description>Administration of ondansetron 4 mg or 8 mg according to weight</description>
    <arm_group_label>Ondransetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 2 vomits in the last 4 hours.

          -  Negative tolerance test.

          -  Signature of the informed consent by the parents or legal guardians.

          -  Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting.

          -  Patients weighing 15 kg or more.

        Exclusion Criteria:

          -  Altered conciousness.

          -  Sospected acute abdomen (appendicitis, invaginations...).

          -  Suspicion or presence of obstructive disease.

          -  Known severe digestive disease (ChronÂ´s disease, ulcerative colitis...).

          -  Suspected food poisoning.

          -  Allergy to any of the drugs used in the study.

          -  Severe dehydration.

          -  Bilious vomiting.

          -  Previous abdominal surgery.

          -  Pathology that may affective degree of hydration of the patient (kidney failure,
             hypoalbuminemia..).

          -  Admission requirement or intravenous rehydration for any reason.

          -  Concomitant use of apomorphine.

          -  In relation to the possible lengthening of the QT, patients with problems of previous
             arrhythmia should be excluded or that they are receiving concomitant medication that
             can lengthen the QT, that have electrolyte disturbances.

          -  Patients receiving other serotonergic drugs.

          -  Patients who have undergone a previous adenotonsillectomy.

          -  Patients with hypocalcemia and/or hypomagnesemia.

          -  Patients with hereditary fructose intolerance.

          -  Diabetes patients.

          -  Lactose intolerant patients.

          -  Patients with indication of the low sodium diets.

          -  Hypersensitivity to ondansetron or other antagonists of the 5-HT3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lizar Aguirre Pascasio, Dr</last_name>
    <phone>945007374</phone>
    <email>LIZAR.AGUIRREPASCASIO@osakidetza.eus</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Basque Health Service</investigator_affiliation>
    <investigator_full_name>Lizar Aguirre Pascasio</investigator_full_name>
    <investigator_title>Doctor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

